X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Addition of systemic antifungal agent, Mycamine (micafungin sodium, Funguard® in Japan) from Astellas, will support Sandoz drive to ensure responsible use of antimicrobials, through targeted use of most appropriate therapies.
Lead Product(s): Micafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mycamine
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: $62.5 million
Deal Type: Acquisition August 28, 2023
Details:
Sandoz will acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas. Addition of Mycamine® will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies.
Lead Product(s): Micafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mycamine
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 23, 2023
Details:
Micafungin-Generic (micafungin for injection) for Injection, 50 mg/vial and 100 mg/vial, single-dose vials,also used to prevent fungal infections in patients who are having a stem cell transplant.
Lead Product(s): Micafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Micafungin Sodium-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
With the approval, MYCAMINE is the first antifungal drug approved in the United States specifically for the treatment of invasive candidiasis for this patient population.
Lead Product(s): Micafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mycamine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
